Evidence map›Paper›PMID 41142421›Full record

ArticleMaterials today. Bio2025

Rational design of ultrabright NIR-II nanofluorophores with enhanced photothermal conversion efficiency for targeted chemodynamic-hypothermal photothermal therapy of hepatocellular carcinoma.

Gui-Long Wu, Senyou Tan, Fan Wu, Hao Xiao, Bibo Zhao, Chaoqiang Li, Jinkang Zhen, Xiao Tang, Qinglai Yang, Guodong Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gui-Long WuDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Senyou TanDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Fan WuDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Hao XiaoDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Bibo ZhaoDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Chaoqiang LiDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Jinkang ZhenDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Xiao TangDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Qinglai YangDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Guodong ChenDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) ranks among the most prevalent and lethal cancers worldwide. Near-infrared II (NIR-II) phototheranostic strategy provides the potential for non-invasive diagnosis and treatment of HCC. However, the NIR-II-based phototheranostic for HCC encounters two primary challenges: the limited photothermal conversion efficiency (PCE) requiring high-temperature hyperther-mia, and low quantum yields leading to imprecise therapeutic localization and non-specific uptake in normal liver tissue, compromise the selectivity, safety, and efficacy of the NIR-II phototheranostic. This study employing molecular engineering systematic optimization of three molecules (IR-FDBT, IR-FDA, IR-FDHT) yielded the optimal IR-FDHT to address these limitations. IR-FDHT features thienothiophenes-functionalized alkyl chains, which alleviate aggregation-caused quenching (ACQ) in aqueous media and enhance the accuracy of NIR-II fluorescence imaging upon tumor accumulation. Additionally, synergistic S···N/S···O intramolecular interactions in IR-FDHT enhance π-conjugation and conforma-tional locking, yielding a significant bathochromic shift and a high PCE of 52.5%, when synergistically integrated with mild hypothermal phototherapy (HPTT) and en-hanced chemodynamic therapy (ECDT), markedly improves phototherapeutic efficacy and safety. Fur-thermore, the self-assembled FDHT-SP94-Fc nanoparticles, which integrate optimized photophysical properties with biological targeting capabilities, markedly enhance phototheranostic specificity and efficacy and provide a paradigm for the selectivity, safety, and effectiveness of HCC NIR-II photo-theranostics.

Indexed as

Hepatocellular carcinoma (HCC)Mild hypothermic photothermal therapy (HPTT)Molecular engineeringNIR-II phototheranosticsTargeted nanoparticles

Identifiers

PMID41142421
PMCPMC12547213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.